Abstract
FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.
Original language | English |
---|---|
Journal | Expert Review of Anticancer Therapy |
Volume | 14 |
Issue number | 5 |
Pages (from-to) | 595-620 |
Number of pages | 26 |
ISSN | 1473-7140 |
DOIs | |
Publication status | Published - May 2014 |
Keywords
- Humans
- Lung Neoplasms
- Multimodal Imaging
- Positron-Emission Tomography
- Tomography, X-Ray Computed